| Literature DB >> 19917536 |
Vicente Alberola Candel1, Alfredo Carrato Mena, Eduardo Díaz-Rubio García, Pere Gascón Vilaplana, Manuel González Barón, Miguel Martín Jiménez, Emilio Alba Conejo, Javier Cassinello Espinosa, Ramon Colomer, Juan Jesús Cruz Hernández, Agustí Barnadas i Molins, Carlos Camps Herrero, Ana Ma Casas Fernández de Tejerina, Joan Carulla Torrent, Manuel Constenla Figueiras, Joaquin Gavilá Gregori, Ma Dolores Isla Casado, Bartomeu Massuti Sureda, Mariano Provencio Pulla, César Augusto Rodríguez Sánchez, Jaime Sanz Ortiz.
Abstract
Treatment of anaemia is a very important aspect in the management of cancer patients. In order to carry out a consensus process about the use of erythropoietic stimulating agents (ESAs) in cancer patients, the Spanish Society of Medical Oncology (SEOM) elaborated a working group which coordinated a panel of medical oncology specialists. This working group has reviewed the main issues about the use of ESAs. In addition a consensus meeting was held in Madrid on 25 April 2007. The following conclusions were made: Since ESA treatment increases the haemoglobin (Hb) level and decreases the red blood cell (RBC) transfusion requirements, ESAs should be used within the approved indications in patients undergoing chemotherapy treatment, beginning at a Hb level below 11 g/dl and maintaining it around 12 g/dl, with iron supplements if necessary. Neither increasing the ESA dose in nonresponders nor the use of ESAs in the treatment of chronic cancer-related anaemia is recommended.Entities:
Mesh：
Substances：
Year: 2009 PMID： 19917536 DOI： 10.1007/s12094-009-0435-6
Source DB: PubMed Journal: Clin Transl Oncol ISSN： 1699-048X Impact factor: 3.405